3D bioprinted perfusable vascular channels using BioFlex Bioink.
CollPlant
Rehovot, Israel -- CollPlant, a regenerative and aesthetic medicine company developing technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced the launch of BioFlex, a ready-to-print rhCollagen-based kit designed for Digital Light Processing (DLP) 3D bioprinting applications.
BioFlex is engineered to support the biofabrication of advanced tissue models for drug discovery, as well as the development of engineered tissues and transplantable organs. The ready-to-print system includes Collink.3D™ 50, a biodegradable polymer component, together with proprietary photoactive agents optimized for high-resolution DLP printing.
By following the BioFlex formulation and printing guidelines, users can efficiently generate customized, high-performance bioinks with tunable mechanical properties, enabling precise fabrication of complex, biologically relevant structures.
The integrated solution eliminates the need for extensive component screening and streamlines formulation development, enabling researchers and industry partners to significantly reduce development time while achieving constructs with precisely controlled physical properties, including enhanced tensile strength, elasticity, reduced brittleness, and improved structural integrity, according to the company.
Designed to serve both academic laboratories and industrial R&D environments, BioFlex supports advanced applications in 3D bioprinting, tissue engineering, and regenerative medicine, facilitating faster translation from concept to functional tissue constructs.
Biofabricated constructs produced using BioFlex demonstrate enhanced mechanical performance, consistency, and safety, supporting advanced applications in tissue engineering and regenerative medicine.
